TRPV2 and neoplasm: HT-29–TRPV2 tumours were more strongly suppressed under these conditions in the TRRV2–PCNH + Laser group than in the other treatment groups (Fig. 5e), perhaps indicating selective targeting of TRPV2-overexpressing cells by TRRV2–PCNH.